Pricing Log in Create free account
Saturday 17 October 2026 Export NEO’s income statement to Excel — free account

NeoGenomics, Inc.

NEO Healthcare Diagnostics & Research

NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

16.65 0.60 −3.48%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−24.5×
Dividend yield
—
F-score
4/9
Altman Z
1.79
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.97
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — 1 — — — — 2 — 1 — —
Insider Ownership 2.80%

Capital & Financial Ratios $m

Market Cap 2,220.00
Revenue 766.30
Net Income (51.88)
Free Cash Flow (5.29)
Net Debt 232.73
Current Ratio 3.60 (at or above 1.5: strong)
Debt/Equity 0.48 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (24.50) (negative: loss-making)
P/S ratio 2.82
P/B ratio 2.75
Past 5Y EPS Growth —
This Y EPS Growth 56.06% (at or above 15%: strong)
Next Y EPS Growth 83.01% (at or above 15%: strong)
Next Y revenue growth 10.66% (at or above 10%: strong)
Next 5Y EPS Growth 55.85% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.4×, against a ten-year median of 3.7×; over the ten years it ranged from 1.4× in 2025 to 12.9× in 2020.
P/S against its own 10 years 29.60%
10-year low 10-year high
P/B against its own 10 years 45.60%
10-year low 10-year high
EV/Sales against its own 10 years 37.82%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 415 387 160 146
Receivables 131 151 159 175
Inventory 24 27 29 27
Other 8 12 7 10
597 596 376 381
2023 2024 2025 Q'26
Payables 20 22 23 21
ST’ Debt — 201 — —
Other 2 0 1 0
96 301 88 106

Compound Annual Growth %

10y 5y 3y
Sales 21.97% 10.35% 12.58%
Cash Flow (1.99%) 29.07% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 14.85% 3.80% (5.71%)

Revenue $m

Mar Jun Sep Dec Year
’26 187 202 — — —
’25 168 181 188 190 727
’24 156 165 168 172 661
’23 137 147 152 156 592
’22 117 125 129 139 510
’21 116 122 121 126 484
’20 106 87 125 126 444
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (8) 20 — — —
’25 (25) 20 9 1 5
’24 (26) 14 9 10 7
’23 (13) (2) (5) 18 (2)
’22 (29) (17) (16) (4) (66)
’21 2 (1) (8) (20) (27)
’20 (7) 2 1 6 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) 12 — — —
’25 (30) 14 1 (4) (20)
’24 (31) 1 (2) (2) (34)
’23 (23) (9) (10) 11 (31)
’22 (37) (15) (24) (8) (85)
’21 (14) (23) (23) (32) (91)
’20 (12) (3) (7) (6) (28)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.13) 0.02 — — —
’25 (0.20) (0.35) (0.21) (0.08) (0.84)
’24 (0.21) (0.15) (0.14) (0.12) (0.62)
’23 (0.25) (0.19) (0.15) (0.11) (0.70)
’22 (0.40) (0.28) (0.30) (0.18) (1.16)
’21 (0.19) 0.59 (0.17) (0.34) (0.07)
’20 (0.07) (0.06) 0.02 0.13 0.04
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 5.49 7.12 7.08 12.04 20.47 29.66 6.00 8.71 12.77 4.72

Analyst estimates 2026–2028

Powerpack
High 9.88 11.63 19.04 30.00 57.07 61.57 35.34 21.22 19.00 19.11
People
People Employees 968 1,030 1,500 1,700 1,700 2,000 2,100 2,100 2,200 2,500
Revenue/emp, $m 0.24 0.23 0.18 0.24 0.26 0.24 0.24 0.28 0.30 0.29
Income, $m
Income, $m Revenue 232 240 277 409 444 484 510 592 661 727
Gross margin, % 42.32 42.44 45.99 48.15 41.83 38.62 36.86 41.34 43.92 43.21
EBT (8) (3) 4 4 (14) (15) (159) (97) (81) (110)
EBT margin, % (3.38) (1.10) 1.38 0.89 (3.16) (3.11) (31.26) (16.41) (12.21) (15.16)
Net income (6) 0 3 8 4 (8) (144) (88) (79) (108)
Depreciation 27 23 22 31 40 56 72 75 75 70
Per share, $
Per share, $ Revenue 2.99 3.02 3.23 4.07 4.09 4.04 4.10 4.71 5.22 5.68
Earnings (0.39) (0.14) 0.03 0.08 0.04 (0.07) (1.16) (0.70) (0.62) (0.84)
Cash flow 0.28 0.23 0.52 0.23 0.01 (0.22) (0.53) (0.02) 0.06 0.04
Capex (0.10) (0.17) (0.17) (0.20) (0.27) (0.53) (0.15) (0.23) (0.32) (0.19)
Free cash flow 0.18 0.05 0.36 0.03 (0.25) (0.76) (0.68) (0.24) (0.27) (0.15)
Book value 2.11 2.17 3.74 5.05 6.39 9.24 8.03 7.50 7.12 6.53
Shares, m 78 79 86 100 109 120 124 126 127 128
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 417.86 1,794.67 0.00 0.00 0.00 0.00 0.00
P/S 2.89 2.88 3.90 7.19 13.15 8.45 2.22 3.38 3.16 2.07
P/B 4.09 4.03 3.37 5.79 8.42 3.69 1.13 2.13 2.31 1.80
EV/Sales 3.27 3.25 4.25 7.01 12.89 8.50 2.42 3.60 3.39 2.60
EV/FCF 54.37 179.44 38.58 858.01 (207.22) (45.32) (14.55) (69.39) (65.86) (95.87)
Cash, $m
Cash, $m Operating cash flow 21 18 45 23 1 (27) (66) (2) 7 5
Capex (8) (14) (14) (20) (29) (64) (19) (29) (41) (25)
Free cash flow 14 4 30 3 (28) (91) (85) (31) (34) (20)
Balance, $m
Balance, $m Working capital 41 49 43 227 376 594 515 501 295 288
Total debt 101 100 106 100 177 540 542 538 541 342
Net debt 89 87 96 (73) (119) 25 104 123 154 182
Shareholders’ equity 164 172 320 507 694 1,108 998 942 902 837
Returns, %
Returns, % ROA (8.95) (3.21) 1.43 1.32 0.49 (0.58) (7.99) (5.14) (4.74) (7.21)
ROIC 0.53 0.70 1.51 1.87 (1.52) (6.55) (8.94) (6.33) (5.45) (7.11)
ROE (16.51) (6.52) 2.47 1.93 0.69 (0.93) (13.70) (9.07) (8.54) (12.42)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

NeoGenomics, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BLLN BillionToOne, Inc. $4.9B 95.0× 99.4× +64.40% (above 0%: growing) n/m +400.65% (above 0%: growing) 70.45% 5.03% Compare
ADPT Adaptive Biotechnologies Corporation $4.1B — (loss-making) — (loss-making) +21.53% (above 0%: growing) n/m +42.04% (above 0%: growing) 71.82% (22.04%) Compare
VCYT Veracyte, Inc. $3.6B 29.9× 45.1× +15.49% (above 0%: growing) n/m +32.95% (above 0%: growing) 72.21% 15.29% Compare
CDNA CareDx, Inc. $3.5B 29.7× 2,967× +52.23% (above 0%: growing) n/m +223.42% (above 0%: growing) 73.50% 85.81% Compare
NEO NeoGenomics, Inc. $2.2B — (loss-making) — (loss-making) +11.21% (above 0%: growing) n/m −16.18% (below 0%: shrinking) 45.56% (4.85%)
WGS GeneDx Holdings Corp. $2.1B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
PSNL Personalis, Inc. $1.7B — (loss-making) — (loss-making) +29.96% (above 0%: growing) n/m −123.46% (below 0%: shrinking) 21.21% (150.25%) Compare
OPK OPKO Health, Inc. $1.2B — (loss-making) — (loss-making) +4.32% (above 0%: growing) n/m +46.46% (above 0%: growing) 48.92% (4.26%) Compare
CSTL Castle Biosciences, Inc. $1.0B — (loss-making) — (loss-making) +20.14% (above 0%: growing) n/m −43.33% (below 0%: shrinking) 77.11% (2.96%) Compare
Median of peers $2.8B 29.9× 99.4× +20.83% — +37.50% 71.13% (3.61%)

All 52 Diagnostics & Research stocks →

NeoGenomics, Inc. (NEO) key facts

  • Strength: NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
  • NeoGenomics, Inc. (NEO) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NEO traded at $16.65, a market capitalization of $2.2 billion.
  • Return on equity was −12.4% and debt-to-equity 0.48.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.79 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

NeoGenomics, Inc. (NEO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NEO · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com